RxDoctor Payments Data

Robert Freele, MD

Psychiatry · Dallas, TXNPI 1851317101

Payments from drug & device makers

$9,130in general payments, 2019–2025

Across 515 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$877
  • Supernus Pharmaceuticals, Inc.$666
  • Neurocrine Biosciences, Inc.$586
  • Sunovion Pharmaceuticals Inc.$492
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$8,82797%
  • Education$3033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,130 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$407,062
Medicare patients
368
Services billed
2,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine34$452,628
IngrezzaValbenazine Tosylate26$215,633
Invega SustennaPaliperidone Palmitate29$84,758
VyvanseLisdexamfetamine Dimesylate75$33,205
BelsomraSuvorexant53$23,183
Lisdexamfetamine Dimesylate72$16,467
TrintellixVortioxetine Hydrobromide21$14,811
SuboxoneBuprenorphine Hcl/Naloxone Hcl16$11,415
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine164$7,900
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine278$6,667
Aripiprazole51$6,369
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl67$6,190
Lurasidone Hcl11$5,923
Ziprasidone Hcl42$4,253
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$3,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$877$452,62834 claims
Neurocrine Biosciences, Inc.Ingrezza$586$215,63326 claims
Johnson & JohnsonInvega Sustenna$243$84,75829 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$36$48,01596 claims
MerckBelsomra$71$23,18353 claims
Indivior Inc.Suboxone$58$11,41516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →